Share on StockTwits

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) saw unusually large options trading on Thursday. Stock investors acquired 3,097 call options on the stock, AnalystRatingsNetwork reports. This represents an increase of approximately 231% compared to the average volume of 937 call options.

A number of analysts have recently weighed in on ISIS shares. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of ISIS Pharmaceuticals in a research note on Thursday. They now have a $70.00 price target on the stock. Separately, analysts at Laidlaw initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating on the stock. Finally, analysts at Laidlow & Co. initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating and a $52.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $44.92.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded up 0.81% on Thursday, hitting $39.90. The stock had a trading volume of 3,273,917 shares. ISIS Pharmaceuticals has a 52 week low of $22.25 and a 52 week high of $62.66. The stock has a 50-day moving average of $32.59 and a 200-day moving average of $36.46. The company’s market cap is $4.698 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Analysts expect that ISIS Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.